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Abstract Pathophysiology of delayed cerebral ischemia
and cerebral vasospasm following aneurysmal subarachnoid
hemorrhage is still poorly recognized, however free radicals
are postulated as one of the crucial players. This study was
designed to scrutinize whether the concentration of free
radicals in the peripheral venous blood is related to the
occurrence of delayed cerebral ischemia associated with
cerebral vasospasm. Twenty-four aneurysmal subarachnoid
hemorrhage patients and seven patients with unruptured
intracranial aneurysm (control group) have been studied.
Free radicals in patients’ blood have been detected by the
electron paramagnetic resonance (CMH.HCl spin probe,
150 K, ELEXSYS E500 spectrometer) on admission and at
least 72 h from disease onset. Delayed cerebral ischemia
monitoring was performed by daily neurological follow-up
and transcranial color coded Doppler. Delayed cerebral
ischemia observed in six aneurysmal subarachnoid hemor-
rhage patients was accompanied by cerebral vasospasm
in all six cases. No statistically signiﬁcant difference in
average free radicals concentration between controls
and study subgroups was noticed on admission (p= .3;
Kruskal–Wallis test). After 72 h free radicals concentration
in delayed cerebral ischemia patients (3.19 ± 1.52 mmol/l)
differed signiﬁcantly from the concentration in aneurysmal
subarachnoid hemorrhage patients without delayed cerebral
ischemia (0.65 ± 0.37 mmol/l) (p= .012; Mann–Whitney
test). These ﬁndings are consistent with our assumptions
and seem to conﬁrm the role of free radicals in delayed
cerebral ischemia development. Preliminary results pre-
sented above are promising and we need perform further
investigation to establish whether blood free radicals con-
centration may serve as the biomarker of delayed cerebral
ischemia associated with cerebral vasospasm.
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Introduction
Regardless the high disability and mortality that is related
with the severity of aneurysmal subarachnoid hemorrhage
(aSAH) by itself, the ﬁnal long-term outcome is greatly
affected by the aSAH complications. Delayed cerebral
ischemia (DCI) associated with cerebral vasospasm remains
a major cause of disability and death in aSAH survivors [1].
Typically it develops between days 4 and 10 after aneurysm
rupture and subarachnoid bleeding [1, 2]. Despite extensive
basic studies the pathophysiology of DCI and cerebral
vasospasm remains recognized incompletely. Generally, it
is known, that the presence of blood in the subarachnoid
space results in contact of hemoglobin decay products with
the abluminal side of the vessels; this initiates a multifaced
cascade of events culminating in arterial narrowing. Among
different mechanisms involved in this process free radicals
and oxidative stress are postulated as one of the crucial
players [3, 4]. Based on this knowledge many attempts with
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free radicals scavengers (tirilazad mesylate just to men-
tioned most often investigated) were made to prevent and/or
to treat DCI and cerebral vasospasm. In experimental stu-
dies positive effects were found, however, in human none of
them are recommended as a routine therapy of proven
efﬁcacy [5, 6]. Still very little is known about the sig-
niﬁcance of markers related to oxidative stress that may
indirectly prove the role of free radicals in the pathophy-
siology of DCI and cerebral vasospasm. Elevated free fatty
acids (markers of lipids peroxidation) were noticed in cer-
ebrospinal ﬂuid (CSF) of patients with DCI [7]. Pyne-
Geithman et al. investigated antioxidant response in ten
aSAH patients and found an elevated activity of glutathione
peroxidase in CSF of patients with vasospasm [8]. The
general conclusion of these studies is in patients with DCI
and cerebral vasospasm there is an increased oxidative
stress and an imbalance between prooxidants and anti-
oxidants. The electron paramagnetic resonance (EPR)
combining with the spin trapping technique is a method of
choice to investigated free radicals [9, 10]. The application
of EPR to studies on human blood have enabled discovery
of the mechanisms of formation and decay of globin-based
free radicals [11]. To the best of our knowledge, the con-
centration of free radicals in blood of patients with sub-
arachnoid hemorrhage wasn’t analyzed so far.
This study was designed to scrutinize whether the con-
centration of free radicals in the peripheral venous blood
increases in the course of aSAH and whether it is related to
the occurrence of DCI associated with cerebral vasospasm.
We aimed particularly to determine if the blood free radicals
concentration may serve as the biomarker of DCI associated
with cerebral vasospasm in the aSAH patients. For this
purpose the correlation between free radicals concentration,
mean ﬂow velocity (MFV) in the cerebral arteries and DCI
occurrence was studied.
Material and Methods
Study Group
Twenty-four patients admitted to the Neurosurgery
Department of University Hospital in Krakow (Poland)
consecutively between November 2012 and August 2013
with diagnosis of aneurysmal subarachnoid hemorrhage
were studied. Study group consisted of 11 women (45.83%)
and 13 men (54.17%) median age of 58.5 years (range
28–80 years). The inclusion criteria were as follow: age
between 18 and 80 years, diagnosis of subarachnoid
hemorrhage (based on head non-contrast computed tomo-
graphy or lumbar puncture), intracranial aneurysm (IA)
presence conﬁrmed in the angio-CT (computed tomo-
graphy), angio-magnetic resonance imaging (MRI), or
cerebral digital subtractive angiography (DSA) and disease
onset less then 48 h before admission. The exclusion criteria
were additionally: known medical conditions related with
increased formation of free radicals (trauma, inﬂammatory
disease, and malignancy), the history of recent (less then
4 weeks) immunosuppressive or steroid treatment, critical
condition of the patient on admission (grade 5 in Hunt and
Hess scale, Glasgow Coma score (GCS) of 3–5), pregnancy
and breastfeeding, concomitant participation in other trials.
Patient’s medical history was collected based on the
interview (if possible) and provided medical records. A
general physical and neurological examination was per-
formed by the study neurosurgeon on admission, and the
patients were graded in the Hunt and Hess [12] and World
Federation of Neurological Surgeons (WFNS) scale [13].
Two scales to follow the clinical condition of aSAH patients
were used since Hunt and Hess grading system is widely
known and well entrenched in the literature and WFNS
contains the component of GCS that closely correlates with
clinical outcome [14]. The initial head CT scan was ana-
lyzed in each case and the grade in the Fisher scale was
determined [15]. In the course of hospitalization neurolo-
gical examination was performed on everyday basis or more
frequently if required by the changes of the patient’s clinical
condition. Patients’ 30-day outcome was determined with
use of modiﬁed Rankin Scale (mRS) [16]. All aSAH
patients were administered oral nimodipine as the preven-
tion of DCI associated with cerebral vasospasm [17].
This study was conducted in accordance with the ethical
standards laid down in the Declaration of Helsinki (1964)
and its design was approved by the local University Ethical
Committee (protocol number KBET/152/B/2012).
Control Group
Seven patients admitted to the Neurosurgery Department with
diagnosed unruptured IA (angio-CT/MRI or DSA) were
recruited as the control subjects. Four women (57.14%) and
three men (42.86%) median age of 55 years (range 32–65
years) were included. The same exclusion criteria as in the
study group were applied. Patient’s medical history was col-
lected and general physical and neurological examination was
performed by the study neurosurgeon on admission.
Blood Samples and EPR Spectroscopy
Peripheral venous blood was collected into the 2.5 ml L-
heparin vacutainer containing 1.25 ml of stock solution.
Blood sampling was carried out twice in the study group—
on days: 0 (admission), 3–7 and once in the control group
(admission).
To overcome the technical difﬁculties associated with
low concentration and short life time of free radicals in
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biological samples, the solution of spin probe CM-H·HCl
(1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrroli-
dine·HCl, C10H19NO3·HCl) and Ar-ﬂushed 20 mM Krebs-
HEPES pH.7.4 buffer was used (stock solution). Prepared
blood samples were injected into the quartz high precision
EPR tubes and immediately frozen in liquid nitrogen (LN).
At the same time reference samples containing stock solu-
tion were prepared.
All EPR measurements were performed at 150 K tem-
perature (ER 4111 VT variable temperature unit) by using
the Bruker Elexsys E-500 X-band spectrometer equipped
with ER TM110 cavity, operating at 9.4 GHz, 2 mW power
and 0.1 mT modulation amplitude. Free radicals con-
centration was determined by comparison of the integral
signal intensity of the investigated samples with that of the
TEMPO ([2,2,6,6-tetramethylpiperidin-1-yl]oxyl) standard
solutions of know concentrations of the paramagnetic cen-
ters (Fig. 1).
DCI and Cerebral Vasospasm Monitoring
DCI was diagnosed according to recognized clinical criteria
[1, 18].
All aSAH patients were monitored for the presence of
cerebral vasospasm with use of transcranial color-coded
Doppler (TCCD). Study design assumed TCCD examina-
tion in all aSAH patients every other day, starting from the
admission day or more frequently if required by the changes
of the patient’s clinical condition. Control subjects were
examined with use of TCCD once—on admission. TCCD
was performed by the trained neurosurgeon (certiﬁed skills)
with use of Aloka ProSound 3500SX ultrasound. Cerebral
vasospasm was diagnosed according to published criteria
[19, 20]. This way to monitor patients was chosen based on
recommendations of American Heart Association/American
Stroke Association published in Stroke in 2012 [18], with
the awareness that TCCD has a lower sensitivity and spe-
ciﬁcity to diagnose arterial narrowing then CT/MRI
angiography or digital subtraction angiography [1].
Statistical Analysis
Quantitative results are presented as median with lower and
upper quartile and minimum and maximum value. Data
were compared across groups using Mann–Whitney test
(two groups) or the Kruskal–Wallis test with the Bonferroni
post-hoc tests (more than two groups) due to the lack
of normality or the ordinal scale of responses. The
Shapiro–Wilk test was used to assess normality.
p values <.05 were considered statistically signiﬁcant.
The analyzes were performed using SPSS Statistics v.21
(IBM, New York, USA).
Results
Characteristics of the aSAH Patients
The clinical proﬁle of studied aSAH patients is presented in
Table 1. There were four deaths in the study group
(16.67%). One patient died due to severe aSAH (ruptured
BA aneurysm) and massive edema in the posterior fossa.
Another patient developed pneumonia and died despite
aggressive treatment. Two patients developed DCI asso-
ciated with severe cerebral vasospasm and, consequently,
cerebral infarction resulting in massive brain edema.
Characteristics of the DCI Patients
Six aSAH patients (25% of study group) developed DCI
5–10 days after subarachnoid bleeding. DCI group con-
sisted of three men and three women, median age of 56.5
years (range 28–73 years). None of DCI patients suffered
from coronary artery disease, peripheral artery disease, or
diabetes mellitus. Sixty-seven percent of DCI patients has
diagnosed preexisting arterial hypertension. Three DCI
patients were active cigarette smokers (67%) and one
patient had a history of alcohol abuse (17%). The median of
Hunt and Hess grade on admission in DCI patients was 3
and the median of WFNS grade was 1.5. The median of
Fig. 1 X-band EPR spectrum of
the oxidized CMH spine probe
(CM•) registered at 150 K (left)
and calibration curve used for
concentration determination
(right). In the onset the formula
of TEMPO, correlation
parameter R2 and question of
straight line are given in the
onset
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Fisher grade for the initial head CT scan was 3. In three
DCI patients (50%) the cause of subarachnoid hemorrhage
was the rupture of the anterior communicating artery
(ACoA) aneurysm, in another two (33%)—the rupture of
middle cerebral artery (MCA) aneurysm and in one (17%)
—internal carotid artery (ICA) aneurysm rupture. Four DCI
patients (67%) had their aneurysm secured by clipping and
another two (33%)—by coiling (ACoA and ICA aneur-
ysm). Two DCI patients (33%) died due to cerebral
infarction and brain edema resulting from DCI associated
with severe cerebral vasospasm. At day 30 post aSAH
average mRS for DCI patients was 4.5 ± 1.2. This outcome
have been worse than the other patients’ in the study group
and the difference is statistically signiﬁcant (p= .018,
Mann–Whitney test).
DCI and Cerebral Vasospasm
Neurological deterioration diagnosed as DCI in six aSAH
patients was scored for 5, 6, 7, 14, 16, and 24 points in NIH
Stroke Scale. Neurological symptoms were accompanied by
the increase of MFV in anterior cerebral artery and/or
middle cerebral artery meeting the TCCD criteria of cere-
bral vasospasm in all six cases. In two patients aggressive
management of DCI resulted in resolution of neurological
symptoms within 3–5 days from the onset of symptoms. No
endovascular interventions were implemented. Simulta-
neously decrease of MFV in serial TCCD studies was
observed in these two patients that proves the resolution of
cerebral vasospasm. In the remaining four patients intensive
treatment of DCI did not bring improvement of their neu-
rological status. In these patients head CT scan performed
24–48 h from the new neurological symptoms onset
revealed cerebral infarction corresponding to the vessel(s)
affected by cerebral vasospasm. After 6 weeks this ﬁnding
was conﬁrmed in control head CT in the DCI patients who
survived (two patients).
Blood Free Radicals
The study of the free radical in the peripheral venous blood
was performed by EPR spectroscopy with use of CMH, an
effective cell permeable membrane spin probe for the
quantiﬁcation of reactive oxygen species (ROS) [21–25].
This spin probe CMH react mostly with superoxide radicals
(Scheme 1) but also peroxyl radicals, peroxynitrite, nitrogen
dioxide were as the one is not sensitive to nitric oxide and
hydrogen peroxide [21–25]. The oxidation of CMH leads to
the formation of the paramagnetic, EPR active, 3-
methoxycarbonyl-proxyl nitroxide (CM•) [26]. The con-
centration of CM• is proportional to the concentration of the
oxidant species, manly (both extra-cellular and intracellular)
[21–25]. CMH detects both extra-cellular and intracellular
superoxide radicals The typical EPR spectrum of the oxi-
dized spin probe registered at 150 K (left) and calibration
curve used for concentration determination (right) are given
in Fig. 1.
Scheme 1 Reaction scheme of CMH spin probe with superoxide
radicals
Table 1 Baseline characteristics of the study group
Patients with aneurysmal SAH n= 24
Age median (year) 58.5
Sex
Female 11 (45.83%)
Male 13 (54.17%)
Comorbidities
Arterial hypertension 15 (62.5%)
Coronary artery disease 4 (16.67%)
Peripheral artery disease 4 (16.67%)
History of stroke 3 (12.5%)
Diabetes mellitus type 2 4 (16.67%)
History of smoking 11 (45.83%)
History of alcohol abuse 3 (12.5%)
On admission
Median of Hunt and Hess grade 3
Median of WFNS grade 2
Median of Fisher grade 3
Coexisting intracerebral hematoma needed surgical
evacuation (%)
4 (16.67%)
Aneurysm distribution (no.)—ruptured only
Anterior communicating artery (AcomA) 10 (41.67%)
Middle cerebral artery (MCA) 5 (20.83%)
Internal carotid artery (ICA) 4 (16.67%)
Basilar artery (BA) 3 (12.5%)
Other 2 (8.33%)
Received aneurysm treatment
Coiling 11 (45.83%)
Clipping 13 (54.17%)
Other 0
None 0
White blood cells (x103/μl) 6.75± 1.85
Average mRS 30 days post aSAH ± SD 3.1± 1.8
Deaths 4 (16.67%)
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Blood free radicals concentration in the aSAH patients
groups (with and without DCI) and in the control group was
compared. No statistically signiﬁcant difference in average
free radicals concentration between study groups and con-
trols was noticed on admission (p= .3; Kruskal–Wallis
test). After 72 h or more from the SAH onset (time window
for DCI associated with vasospasm) blood free radicals
concentration in DCI patients (3.18 ± 1.52 mmol/dm3) dif-
fered signiﬁcantly from the concentration in blood of aSAH
patients who didn’t developed DCI (0.65 ± 0.37 mmol/dm3)
(p= .012; Mann–Whitney test) as presented in Table 2.
Blood free Radicals Concentration and MFV
Due to low number of patients in analyzed statistical groups
the correlation between blood free radicals concentration
and MFV in cerebral vessels of aSAH patients could not be
determined. However, the graphical illustration these
dependencies allows to see relation, which may be pro-
mising in the context of further research (Fig. 2).
Greater number of patients in analyzed subgroups would
allow then to apply statistical tests that would express this
relation in numbers.
Discussion
DCI associated with cerebral vasospasm remains the most
important single complication leading to disability and
death in aSAH survivors. Signs of DCI may be reversible
but may also persist or progress in situation of cerebral
infarction, leading to disability or death. The most recent
data reveals that DCI may develop independently of the
radiological vasospasm presence. This most likely results
from the impairments in the arteriolar circulation not visible
angiographically, from the damage to the cerebral tissue in
the ﬁrst 72 h after aneurysm rupture (“early brain damage”),
cortical spreading depression and microthrombosis [27–29].
Aneurysmal bleeding into the subarachnoid space initiates
multifaced cascade of events resulting in inﬂammation and
oxidative stress. Among different mechanisms involved in
DCI and cerebral vasospasm development, free radicals and
oxidative stress are considered to be substantial [3, 4, 30].
The excessive formation of free radicals in subarachnoid
hemorrhage occurs through different pathways like extra-
cellular hemoglobin conversions, disruption of mitochon-
drial respiration, and upregulation of enzymes producing
free radicals: inducible nitric oxide synthase, NADPH oxi-
dase (NOX), xanthine oxidase and other [30].
Six out of twenty-four patients in the study group
developed delayed neurological deterioration accompanied
by the impairments in the cerebral circulation diagnosed as
delayed cerebral ischemia associated with cerebral vasos-
pasm. This proportion is consistent with population-based
studies [31].
The median of age in the study group and in the sub-
group of DCI patients haven’t differed signiﬁcantly (58.5
vs. 56.5 years). Some previous studies found the younger
aSAH patients (<35 years of age, <50 years of age in other
study) more prone to develop DCI associated with cerebral
vasospasm [32, 33] while the other studies have shown
higher incidence of discussed aSAH complication with the
increasing age (>60 years of age) [34]. In the most recent
studies patient’s age wasn’t found to be predictive for DCI
associated with cerebral vasospasm [35] and it is the same
in the presented material. Anyway the there is disagreement
in the literature regarding the relationship between age and
the risk of DCI associated with cerebral vasospasm, and it
has been related to the variety of different deﬁnitions and
terms used to describe this clinical phenomenon and dif-
ferent measurement modalities used in the studies. Similar
percentage of men (23%) and women (27%) in the study
group developed the DCI associated with cerebral vasos-
pasm. Among the comorbidities included in the clinical
characteristics of the study group, the history of preexisting
arterial hypertension is considered to be the risk factor of
DCI associated with cerebral vasospasm [36] and in our
study it was more often in the DCI patients (67%) than in
the entire study group (63%) but the described difference
haven’t met the criteria for statistical signiﬁcance. Several
papers (including prospective studies) suggest cigarette
smoking as the independent predictor of DCI associated
with cerebral vasospasm in the aSAH patients [37, 38].
Table 2 Venous blood free radicals concentration on admission and
after at least 72 h from the SAH onset
Blood free
radicals
concentration
(mmol/dm3)
Study group
—DCI
patients
Study group
—non-DCI
patients
Control
group
p
On admission
Mean± SEM 1.18± 0.48 0.55± 0.16 0.48± 0.12 .3*
95% CI −0.13–2.50 0.20–0.90 0.19–0.78
Median 0.48 0.34 0.49
IQR 1.96 0.35 0.57
After ≥72 H
Mean± SEM 3.18± 1.52 0.65± 0.37 .012**
95% CI 0.70–7.07 −0.19–1.49
Median 2.07 0.34
IQR 5.07 0.26
SEM standard error of the mean, 95% CI 95% conﬁdence interval, IQR
interquartile range
*p for Kruskal–Wallis’ statistics
**p for Mann–Whitney’s statistics
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Presented results conﬁrm this observation—it was 46% of
active cigarette smokers in the study group comparing with
67% in the DCI subgroup. One retrospective study revealed
that nicotine replacement therapy in active smokers with
aSAH may reduce the risk of DCI associated with vasos-
pasm, while another study of similar size have failed to
repeat these results [39]. None of the components of
cigarette smoke has not yet been identiﬁed as a single agent
which will lead to the development of DCI. Smoking leads
to the increased free radicals formation in blood [40] and
this might the promising in the context of the results pre-
sented in this paper. The clinical severity of aSAH eval-
uated with use of Hunt and Hess scale and WFNS haven’t
shown any signiﬁcant difference between all aSAH patients
and DCI subgroup. The median of Hunt and Hess grade on
admission was three in both groups when the result ≥ 3 is
considered increasing the risk of DCI associated with cer-
ebral vasospasm [36, 41]. WFNS haven’t been proved to be
predictive for DCI/cerebral vasospasm [33]. In the 1970s
the relationship between the amount and distribution of
blood in the subarachnoid space on the initial head CT scan
and development of visible angiographically vasospasm
was reported. Since then Fisher grading scale for the clas-
siﬁcation of the admission head CT scans was introduced
into clinical practice and high correlation between DCI
associated with cerebral vasospasm and Fisher grade 3 have
been revealed. Fisher grade of 3 (the median in the study
group and in the DCI subgroup) increases the odds of DCI
development [15, 42–44]. Clipping was applied in more
aSAH patients than coiling (13 vs. 11) in the study group
[45]. More DCI patients received clipping [4] than coiling
[2] of their ruptured IA. It is known that DCI develops more
Fig. 2 Blood free radicals concentration and mean ﬂow velocity (MFV) in cerebral vessels of aSAH patients
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often after clipping then after coiling (International Sub-
arachnoid Aneurysm Trial) and it is consistent with our
observations [43]. The most recent data demonstrate it
doesn’t affect the ﬁnal outcome, except the aSAH patients
who were treated within 4 days after the initial bleeding—in
this particular group DCI is associated with poorer outcome
after coiling then after clipping [46]. All aSAH patients
studied in our material were treated within 48 h from the
aSAH onset.
EPR technique, coupled to a speciﬁc spin probe (CMH:
1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolid-
ine) is here presented as the method of choice to gain a
direct measurement of ROS in biological ﬂuids and tissues.
The correlation between EPR results and data obtained by
various enzymatic assays (e.g., protein carbonyls and thio-
barbituric acid reactive substances) was determined too
[47]. CM-H.HCl has been previously used in studies on
Alzheimer’s disease (liquid samples) and atherosclerosis
(tissue samples) [26, 47–49]. Mechanisms of globin-based
free radicals formation and decay in the human blood were
studied and their baseline concentration was estimated at
1μmol/dm3 in healthy volunteers [11]. To the best of our
knowledge, reports on the concentration of free radicals in
the blood of patients with aneurysmal subarachnoid
hemorrhage are not available. One of our aims was to
investigate whether the concentration of free radicals in the
blood increases in the course of aSAH and whether it is
related to the occurrence of DCT/cerebral vasospasm. EPR
supported by the spin probe (CMH.HCl) was used to
address the issue of detection and measurements of free
radicals in the human venous blood. No statistically sig-
niﬁcant difference in average free radicals concentration
between controls and study groups (patients with/without
DCI, less than 48 h of SAH onset) was demonstrated on
admission. Subsequent measurements in the study group
registered in the time window for DCI/vasospasm [1, 2].
showed a statistically signiﬁcantly higher concentration of
free radicals in patients who developed symptoms of DCI/
vasospasm when compared to aSAH patients who did not
present any of these complications.
Presented results may suggest the relevant contribution
of free radicals in development of DCI and cerebral
vasospasm. It has to be mark the currently published results
are preliminary and the study is in progress.
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